We work Hard to get you posted with latest updates

http://We%20work%20Hard%20to%20get%20you%20posted%20with%20latest%20updates

Spend time learning about the different aspects of that topic from experts in the field.

AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy

Unwrap our new Directory

http://Unwrap%20our%20new%20Directory

Directory

Home
Pharma
Bio-Pharma
MedTech
Veterinary
Cosmetics
Food
.Clinical
.Tech
.edu
.gov
M&A
.VC

Mirum Pharmaceuticals, ATEBRIOZ, Zilurgisertib, Fibrodysplasia Ossificans Progressiva, FOP, PROGRESS Study, Cohort 2, Rare Disease, Genetic Disease, Pediatric Clinical Trial,

Advertisement

cGxPJobs Banner

Mirum Pharmaceuticals Reports Positive PROGRESS Study Results for ATEBRIOZ in Children with Fibrodysplasia Ossificans Progressiva

FOSTER CITY, California — October 26, 2026 Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) announced positive results from Cohort 2 of...

By cGxPwire Editor
October 28, 2026

Read More

Advertisement

cGxPJobs

Recent Posts

01

Pharma

Tonix Pharmaceuticals Reports Phase 3 Data Showing TONMYA® Improved Physical Symptoms and Functional Ability in Fibromyalgia
October 28, 2026
02

Bio-Pharma

Anixa Biosciences Completes Fifth Ovarian Cancer CAR-T Cohort
October 28, 2026
03

MedTech

Vantive Expands HomeAdvantage to Advance Home Dialysis
October 28, 2026
04

Pharma

Merck’s KEYTRUDA Monotherapy Reduces Risk of Disease Progression or Death by 43% in Advanced or Recurrent dMMR Endometrial Cancer
October 28, 2026
05

Pharma

Pfizer’s TALZENNA Plus XTANDI Receives FDA Approval for Earlier Treatment of Metastatic Prostate Cancer
October 28, 2026

Advertisement

Copyright © 2026 cGxP.wire | Made by 3styler

Directory

Home
Pharma
Bio-Pharma
MedTech
Veterinary
Cosmetics
Food
.Clinical
.Tech
.edu
.gov
M&A
.VC

Start typing and press Enter to search

Loading Comments...

Write a Comment...

Email (Required)

Name (Required)

Website